{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:00:27Z","timestamp":1788796827834,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jgar.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T07:40:00Z","timestamp":1724398800000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Cojutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":false,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.08.002_bib0001","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0002","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2024.08.002_bib0003","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1128\/AAC.47.11.3554-3560.2003","article-title":"Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases","volume":"47","author":"Paterson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0004","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jac\/dkz571","article-title":"Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17","volume":"75","author":"Kazmierczak","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0005","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cmi.2019.03.030","article-title":"Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients","volume":"25","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.08.002_bib0006","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2024.08.002_bib0007","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2019.03.007","article-title":"Post-MERINO trial: any role for piperacillin-tazobactam in treating bloodstream infections caused by extended-spectrum beta-lactamase producing Enterobacteriaceae?","volume":"53","author":"Sfeir","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.08.002_bib0008","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0009","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.08.002_bib0010","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0011","doi-asserted-by":"crossref","first-page":"ofx099","DOI":"10.1093\/ofid\/ofx099","article-title":"Comparison between carbapenems and \u03b2-lactam\/\u03b2-lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis","volume":"4","author":"Muhammed","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0012","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijantimicag.2018.07.021","article-title":"Beta-lactam\/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis","volume":"52","author":"Sfeir","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.08.002_bib0013","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijid.2023.01.001","article-title":"Carbapenem-sparing beta-lactam\/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis","volume":"128","author":"Zhang","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0014","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2024.08.002_bib0015","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2024.08.002_bib0016","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2024.08.002_bib0017","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2024.08.002_bib0018","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","article-title":"Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"64","author":"Kang","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2024.08.002_bib0019","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2024.08.002_bib0021","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2024.08.002_bib0023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10096-017-3133-2","article-title":"Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study","volume":"37","author":"Ko","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01813-18","article-title":"Carbapenem versus cefepime or piperacillin-tazobactam for empiric treatment of bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli in patients with hematologic malignancy","volume":"63","author":"Benanti","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02206-22","article-title":"Comparison of the treatment outcome of piperacillin-tazobactam versus carbapenems for patients with bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in areas with low frequency of coproduction of OXA-1: a preliminary analysis","volume":"10","author":"Hoashi","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.08.002_bib0026","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/dkad404","article-title":"Association of piperacillin\/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin\/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study","volume":"79","author":"Rando","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0027","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.02190-12","article-title":"Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum \u03b2-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model","volume":"57","author":"Docobo-P\u00e9rez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0028","doi-asserted-by":"crossref","first-page":"O831","DOI":"10.1111\/1469-0691.12677","article-title":"In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae","volume":"20","author":"Harada","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.08.002_bib0029","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0030","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/jac\/dkz226","article-title":"Inoculum effect of \u03b2-lactam antibiotics","volume":"74","author":"Lenhard","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0031","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00134-004-2222-8","article-title":"Steady-state plasma and intrapulmonary concentrations of piperacillin\/tazobactam 4 g\/0.5 g administered to critically ill patients with severe nosocomial pneumonia","volume":"30","author":"Boselli","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2024.08.002_bib0032","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/CCM.0b013e318170ba21","article-title":"Alveolar concentrations of piperacillin\/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia","volume":"36","author":"Boselli","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2024.08.002_bib0033","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14787210.2021.1976145","article-title":"An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients","volume":"20","author":"Gatti","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2024.08.002_bib0034","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jac\/dkg114","article-title":"Variable susceptibility to piperacillin\/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases","volume":"51","author":"Babini","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0035","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-\u03b2-lactamase-producing Escherichia coli and Klebsiella Species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0036","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jac\/dkv362","article-title":"Impact of the MIC of piperacillin\/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the bacteraemia-MIC project","volume":"71","author":"Delgado-Valverde","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0037","doi-asserted-by":"crossref","first-page":"dlad041","DOI":"10.1093\/jacamr\/dlad041","article-title":"Association between piperacillin\/tazobactam MIC and survival among hospitalized patients with Enterobacterales infections: retrospective cohort analysis of electronic health records from 161 US hospitals","volume":"5","author":"Strich","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.08.002_bib0038","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.08.002_bib0039","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14787210.2023.2169131","article-title":"Jumping into the future: overcoming pharmacokinetic\/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-gram-negative infections with novel beta-lactams","volume":"21","author":"Gatti","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2024.08.002_bib0040","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2024.08.002_bib0041","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/jac\/dkx001","article-title":"Determining \u03b2-lactam exposure threshold to suppress resistance development in Gram-negative bacteria","volume":"72","author":"Tam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0042","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/jac\/dkaa359","article-title":"Early therapeutic monitoring of \u03b2-lactams and associated therapy outcomes in critically ill patients","volume":"75","author":"Al-Shaer","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106727","article-title":"Beta-lactam target attainment and associated outcomes in patients with bloodstream infections","volume":"61","author":"Alshaer","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.08.002_bib0044","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/microorganisms12010151","volume":"12","author":"Gatti","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2024.08.002_bib0045","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.08.002_bib0046","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:25:24Z","timestamp":1734701124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S2213716524001541"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.08.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}